<DOC>
	<DOCNO>NCT00172068</DOCNO>
	<brief_summary>Metastatic bone disease important prognostic factor survival median close two year first diagnosis osseous metastasis . This open-label study investigate safety efficacy zoledronic acid patient breast cancer minimal residual disease bone marrow .</brief_summary>
	<brief_title>Zoledronic Acid Treatment Breast Cancer With Minimal Residual Disease Bone Marrow</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients , primary breast cancer undergone complete primary tumor resection axillary lymph node dissection Evidence minimal residual disease ( disseminated tumor cell bone marrow ) Patients receive one follow adjuvant therapy category : chemotherapy Â± hormonal therapy hormonal therapy alone Inflammatory , metastatic recurrent breast cancer history breast cancer prior currently diagnose case Neoadjuvant chemotherapy , neoadjuvant hormonal therapy , neoadjuvant radiotherapy Prior stem cell rescue/bone marrow transplant History cancer aside nonmelanomatous skin cancer carcinoma situ uterine cervix Additional protocoldefined inclusion / exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Primary breast cancer</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Minimal residual disease</keyword>
	<keyword>Bisphosphonates</keyword>
</DOC>